Angry Patient: Aspirin Stopped Without Discussion

Clinical Scenario

Robert Kane, 60, calls furious about his aspirin being stopped. He has hypertension and hypercholesterolaemia, and was taking amlodipine 10mg, atorvastatin 20mg, and aspirin 75mg. During a routine pharmacist medication review conducted without the patient present, the aspirin was discontinued because it was started for primary prevention with no indication to continue. Robert discovered this when he tried to reorder his prescription. He is angry about not being consulted, worried about stroke risk, and has lost trust in the practice.

What This Case Tests

De-escalating an angry patient; acknowledging and apologising for the process failure (medication changed without patient involvement); explaining the evidence on aspirin for primary prevention (risk of bleeding outweighs cardiovascular benefit in most patients); distinguishing primary from secondary prevention; rebuilding trust after a practice systems failure.

Common Mistakes Trainees Make

The three most common mistakes are: defending the pharmacist or the practice systems rather than acknowledging the process failure (Robert is right to be angry — his medication was changed without his knowledge), restarting the aspirin to appease the patient without explaining the evidence (the pharmacist was clinically correct to stop it, even though the process was wrong), and not distinguishing primary from secondary prevention (aspirin is not recommended for primary prevention in patients without established cardiovascular disease).

The Consultation Challenge

Robert is angry and has every right to be. His medication was changed without his knowledge or consent. The pharmacist was clinically correct — aspirin for primary prevention is no longer recommended — but the process was unacceptable. You need to address both the process failure and the clinical decision.

Start with the process. Acknowledge the failure immediately: "You are absolutely right to be angry. Your medication should not have been changed without discussing it with you first. That is not how we should do things, and I apologise on behalf of the practice." This is not optional — the practice made a mistake, and avoiding accountability will escalate the anger.

Do not blame the pharmacist. "The pharmacist was trying to make sure your medications were safe and up to date, but the way it was done — without speaking to you — was wrong. I am sorry."

Once the anger has de-escalated (and it will, with genuine acknowledgment), explain the clinical reasoning. Aspirin for primary prevention was historically common but the evidence has shifted. Large trials (ARRIVE, ASPREE, ASCEND) have shown that for patients without established cardiovascular disease (no previous heart attack, stroke, or TIA), the bleeding risk from aspirin outweighs the cardiovascular benefit. Robert has hypertension and high cholesterol, but no history of cardiovascular events — this is primary prevention, and aspirin is no longer indicated.

Distinguish this from secondary prevention. If Robert had ever had a heart attack, stroke, or TIA, aspirin would remain essential. In his case, his cardiovascular protection comes from good blood pressure control (amlodipine) and cholesterol management (atorvastatin), not aspirin.

Address his stroke fear specifically. "I understand your worry about stroke. The best protection you have is keeping your blood pressure well controlled and your cholesterol down — and you are doing both of those. The evidence now tells us that adding aspirin on top of that does not reduce your stroke risk further but does increase your risk of bleeding."

Offer to review his overall cardiovascular risk. Calculate his QRISK3 score, review his blood pressure and cholesterol levels, and ensure his current medications are optimised. This demonstrates proactive care and helps rebuild trust.

Time check: Spend the first 4 minutes on de-escalation and process acknowledgment. By minute 7, explain the aspirin evidence. Address the stroke fear between minutes 8-9. Use minutes 10-11 for QRISK review and cardiovascular optimisation. Reserve the final minute for rebuilding trust and follow-up.

How Examiners Mark This Case

Data Gathering and Diagnosis: Examiners assess whether you establish the clinical context (primary versus secondary prevention — has Robert had any cardiovascular events?), understand why the aspirin was originally started, review his current cardiovascular risk factor management, and take a medication history including adherence. Confirming this is primary prevention (no cardiovascular events) is the key clinical fact that supports the pharmacist's decision.

Clinical Management and Medical Complexity: Examiners expect accurate knowledge of the aspirin primary prevention evidence (ARRIVE, ASPREE, ASCEND), the distinction between primary and secondary prevention, and an overall cardiovascular risk assessment (QRISK3). They look for optimisation of existing management rather than restarting aspirin. A trainee who restarts aspirin to end the argument or who cannot explain the evidence will score poorly.

Relating to Others: The dominant domain. Examiners assess whether you acknowledge the process failure genuinely (not defensively), de-escalate the anger before attempting to explain the clinical reasoning, avoid blaming the pharmacist, and rebuild trust through proactive cardiovascular care. Robert should leave understanding why the aspirin was stopped, feeling that the process failure has been acknowledged, and confident that his cardiovascular health is being managed well.

Example Opening

Strong opening: "Hello Robert, I can hear you are really upset about this, and I want to start by saying you are absolutely right to be. Your medication should never have been changed without talking to you first, and I am sorry that happened."

When explaining the evidence: "Now that we have addressed how this was handled, I want to explain why the aspirin was stopped, because the pharmacist was actually right on the clinical side — even though the process was wrong. The evidence on aspirin has changed significantly in recent years. For someone like you — who has never had a heart attack or stroke — aspirin actually causes more harm than benefit because of the bleeding risk."

When addressing stroke fear: "Your best protection against stroke is the blood pressure tablet and the cholesterol tablet you are already taking. Those are doing the heavy lifting. Adding aspirin on top does not reduce your stroke risk further, but it does increase your chance of a serious bleed."

Avoid: "The pharmacist was just following guidelines." (Sounds defensive and dismisses Robert's legitimate grievance about the process).

How This Appears in the SCA

This case combines angry patient management with cardiovascular pharmacology. The examiner assesses whether you can de-escalate effectively, acknowledge the process failure honestly, explain the aspirin evidence clearly, and rebuild trust. Getting drawn into defending the practice or capitulating by restarting aspirin both score poorly.

Key Statistic

The ASPREE trial (2018) of 19,114 healthy adults over 70 showed aspirin for primary prevention increased major bleeding by 38% without reducing cardiovascular events. Current NICE guidance does not recommend aspirin for primary cardiovascular prevention in patients without established cardiovascular disease.

Relevant Guidelines

• NICE CG181: Cardiovascular disease — risk assessment and reduction
• NICE guideline on antiplatelet therapy
• ARRIVE, ASPREE, and ASCEND trial evidence on aspirin for primary prevention.

Frequently Asked Questions

Is aspirin still recommended for primary cardiovascular prevention?

No. Based on large trials (ARRIVE 2018, ASPREE 2018, ASCEND 2018), aspirin for primary prevention in patients without established cardiovascular disease is no longer recommended by NICE. The bleeding risk (particularly GI bleeding and haemorrhagic stroke) outweighs the cardiovascular benefit. Aspirin remains essential for secondary prevention — patients with previous MI, stroke, TIA, or established peripheral vascular disease should continue it.

How do I distinguish primary from secondary cardiovascular prevention?

Primary prevention: interventions to prevent cardiovascular events in someone who has never had one (no previous MI, stroke, TIA, angina, or peripheral vascular disease). Secondary prevention: interventions to prevent recurrence in someone with established cardiovascular disease. The distinction is critical because the risk-benefit calculation for treatments like aspirin differs dramatically between the two groups. Always confirm cardiovascular event history before making prescribing decisions.

How should I handle a medication change made without patient consultation?

Acknowledge the process failure honestly and apologise. Do not deflect blame or make excuses. Then explain the clinical reasoning for the change separately from the process issue. The patient needs to hear two things: (1) the way it was done was wrong, and (2) the actual clinical decision may have been correct. Separating these prevents the process anger from contaminating the patient's ability to hear the clinical explanation.

Should I restart the aspirin if the patient insists?

No — prescribing a medication you believe is not indicated to appease an angry patient is not good practice. Instead, explain the evidence clearly, acknowledge the patient's concern about cardiovascular protection, and demonstrate that their risk is being managed through other medications. If after a full informed discussion the patient still insists, document the conversation and your advice. Ultimately, patient autonomy matters, but the examiner wants to see that you explain the evidence rather than capitulate under pressure.

What is a QRISK3 assessment and when should I use it?

QRISK3 is a validated cardiovascular risk calculator that estimates 10-year risk of heart attack or stroke based on age, sex, ethnicity, blood pressure, cholesterol, smoking status, diabetes, family history, and other factors. A score of 10% or above triggers a conversation about statin therapy per NICE. Calculating QRISK3 in this consultation serves two purposes: it demonstrates proactive cardiovascular management, and it provides Robert with a concrete understanding of his actual risk — which may be reassuring.